Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
L FusoIgnace Vergote

Abstract

Single-agent gemcitabine demonstrated response rates of 11-60% in platinum/paclitaxel-resistant ovarian cancer. Twenty-four patients with epithelial ovarian cancer were treated with gemcitabine 800 mg/m2 on days 1 and 8, carboplatin area under the curve 5 on day 1, and paclitaxel 175 mg/m2 over 3 h on day 1 every 3 weeks for six cycles. Median age was 54 years, and FIGO stage distribution was IIC, 1 patient, III, 18, and IV, 5. A total of 22 (92%) patients completed all the six planned courses of chemotherapy. Doses were reduced in 8 out of 24 (33%) patients. Of the 17 patients with measurable disease, 15 underwent an interval debulking surgery. Prior to interval debulking surgery, all 15 patients had a partial response according to the response evaluation criteria in solid tumors criteria. Overall in the 17 patients with measurable disease, the response rate at the end of the first-line chemotherapy (including interval debulking) was 94% (14 [82%] complete response and 2 [12%], partial response). One patient (6%) received only one cycle due to early progression. Using the CA125 criteria as defined by the Gynecologic Cancer Intergroup, all patients had at least a partial response prior to interval debulking, and the overall res...Continue Reading

References

May 1, 1995·Annals of the Rheumatic Diseases·S E Carsons, J Wolf
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Aug 17, 1993·Biochemical Pharmacology·V W Ruiz van HaperenG J Peters
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K MaasC Bokemeyer
Apr 2, 1998·Cancer Chemotherapy and Pharmacology·S RomanelliF Zunino
Jun 13, 1998·Anti-cancer Drugs·M S AaproS Hatty
Feb 5, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M FriedlanderL Kayitalire
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M MuggiaJ M Small
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen
Feb 24, 2001·Journal of Cancer Research and Clinical Oncology·I B Runnebaum, E Stickeler
May 24, 2001·Seminars in Oncology·R F Ozols
Mar 15, 2002·Seminars in Oncology·Nicholas J Vogelzang
Mar 22, 2003·Gynecologic Oncology·Giuseppe D'AgostinoIgnace Vergote
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M J PiccartW McGuire
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·G B KristensenE Vrdoljak
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Mar 18, 2004·Journal of the National Cancer Institute·Gordon J S RustinJan Vermorken
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin J EdelmanDavid R Gandara

❮ Previous
Next ❯

Citations

May 1, 2007·Women's Health·Fadi Abushahin, Peter G Rose
Nov 20, 2008·Gynecologic Oncology·Siriwan TangjitgamolPisake Lumbiganon
Jul 17, 2019·Biomarkers in Cancer·Ruchika PokhriyalGururao Hariprasad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.